Glaukos Corporation

https://www.glaukos.com

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company dedicated to developing and commercializing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company's mission is to transform vision by pioneering novel, dropless platforms that significantly advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye conditions. Glaukos' global headquarters is located in Aliso Viejo, California.

Glaukos is recognized for pioneering Micro-Invasive Glaucoma Surgery (MIGS) with its iStent family of devices, including iStent, iStent inject W, and iStent infinite, designed to reduce intraocular pressure. The company's product portfolio also includes iDose TR, a sustained-release pharmaceutical implant for glaucoma, and Epioxa/Epioxa HD, a corneal cross-linking therapy for keratoconus, along with the KXL system for corneal health. Glaukos primarily serves ophthalmic surgeons, eye care professionals, hospitals, and surgical centers.

In recent news, Glaukos reported record net sales of $150.6 million in Q1 2026, marking a 41% year-over-year increase, and subsequently raised its full-year 2026 net sales guidance to between $620 million and $635 million. The company also secured a permanent J-code for its Epioxa keratoconus treatment, enhancing reimbursement clarity. Led by Chairman and CEO Thomas W. Burns, Glaukos maintains a strong market position as a leader in MIGS and FDA-approved corneal cross-linking, with significant growth driven by products like iDose TR.

Latest updates

Glaukos Sales Surge 41% on Dropless Therapies, Raises 2026 Guidance

Event summary

  • Glaukos reported record Q1 2026 net sales of $150.6 million, a 41% year-over-year increase.
  • U.S. Glaucoma sales led the growth, rising 58% year-over-year to $93.5 million.
  • The company raised its full-year 2026 net sales guidance to $620-$635 million from a previous range of $600-$620 million.
  • Gross margins improved to approximately 78% (GAAP) and 84% (non-GAAP) in Q1 2026.

The big picture

Glaukos' strong performance underscores the growing demand for minimally invasive glaucoma treatments and the potential of dropless therapies to disrupt the ophthalmology market. The raised guidance signals confidence in the company's commercial execution and the market's receptiveness to its innovative product portfolio, but also highlights the need for continued investment in R&D and sales infrastructure to maintain momentum. The company's focus on expanding its product offerings and geographic reach positions it for continued growth within a multi-billion dollar market.

What we're watching

Growth Sustainability
The continued reliance on iDose TR and Epioxa for growth necessitates monitoring their adoption rates and potential competitive pressures within the dropless glaucoma therapy market. Sustained high growth will require continued innovation and expansion beyond current product offerings.
SG&A Efficiency
While revenue growth is strong, SG&A expenses increased significantly (32%), potentially impacting profitability. Investors should assess Glaukos' ability to manage operating expenses as it scales and whether these costs are sustainable.
Pipeline Progress
Glaukos' long-term success hinges on its pipeline of novel therapies. The pace at which these therapies advance through clinical trials and regulatory approval will be a key determinant of future growth and market leadership.

Glaukos Highlights ESG Progress Amidst R&D Expansion

Event summary

  • Glaukos released its seventh annual Sustainability Report, detailing 2025 initiatives.
  • The company donated over $22 million in product to underserved regions.
  • A new R&D and manufacturing facility broke ground in Huntsville, Alabama.
  • Glaukos completed a climate risk assessment aligned with TCFD recommendations.

The big picture

Glaukos's focus on sustainability aligns with the growing investor demand for ESG-conscious companies within the healthcare sector. The Huntsville facility expansion signals a commitment to long-term growth and innovation, but also introduces operational risks. The adoption of TCFD guidelines demonstrates a proactive approach to climate risk management, which is increasingly important for maintaining investor confidence and securing financing.

What we're watching

Governance Dynamics
The board's oversight of sustainability initiatives will be crucial as Glaukos integrates these factors into long-term strategic planning and capital allocation decisions.
Regulatory Headwinds
Increased scrutiny of ESG disclosures and potential mandatory reporting requirements could impact Glaukos’ reporting practices and necessitate further investment in data collection and verification.
Execution Risk
The success of the Huntsville facility will depend on Glaukos’ ability to manage construction timelines, integrate operations, and attract skilled talent in a competitive labor market.

Glaukos Secures Permanent J-Code for Keratoconus Treatment

Event summary

  • Glaukos has received a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J2789) for its Epioxa™ treatment.
  • The J-code, effective July 1, 2026, is intended to streamline reimbursement for Epioxa by U.S. payers.
  • Epioxa is a photoenhancer used in epithelium-on corneal collagen cross-linking for keratoconus treatment.
  • The treatment offers an incision-free alternative to traditional cross-linking procedures.

The big picture

The assignment of a permanent J-code is a significant step for Glaukos, addressing a key hurdle to broader commercial adoption of Epioxa. Keratoconus, a relatively rare but serious condition, represents a niche market with unmet needs, and streamlined reimbursement is crucial for expanding access to innovative therapies. This development underscores the ongoing importance of navigating the complex U.S. healthcare reimbursement system for medical device and pharmaceutical companies.

What we're watching

Adoption Rate
The actual speed of adoption by providers and the resulting impact on Epioxa sales will depend on the ease of implementation and perceived value of the new J-code.
Payer Response
How consistently commercial payers follow CMS’s lead in coverage and reimbursement will determine the long-term benefit to Glaukos’s revenue stream.
Competitive Landscape
The success of Epioxa’s adoption may accelerate innovation and competition within the corneal cross-linking market, potentially impacting Glaukos’s pricing power.

Glaukos to Report Q1 2026 Results Amidst Dropless Therapy Expansion

Event summary

  • Glaukos Corporation (NYSE: GKOS) will release its Q1 2026 financial results on April 29, 2026, after market close.
  • A conference call and webcast to discuss the results are scheduled for April 29, 2026, at 1:30 PM PT / 4:30 PM ET.
  • Glaukos launched iDose® TR, a long-duration intracameral glaucoma drug therapy, in 2024.
  • The company holds the only FDA-approved corneal cross-linking therapy for keratoconus.

The big picture

Glaukos's focus on 'dropless' therapies represents a significant shift in glaucoma treatment, aiming to reduce patient burden and improve compliance. The company's 2024 launch of iDose TR positions it as a leader in this emerging market, but its success will depend on overcoming adoption hurdles and navigating a competitive landscape. The Q1 2026 results will provide insight into the early performance of this key product and the overall trajectory of Glaukos's innovation strategy.

What we're watching

Market Adoption
The success of iDose TR will hinge on physician adoption rates and patient acceptance of the long-duration therapy, which could significantly impact revenue projections.
Pipeline Progress
Glaukos's ability to advance its 'dropless platform technologies' will be crucial for long-term growth, and investors will scrutinize updates on pipeline milestones.
Competitive Landscape
Increased competition in the glaucoma treatment space, particularly with alternative drug delivery methods, could pressure Glaukos’s market share and pricing power.

Glaukos Presents Data at ASCRS, Highlights Corneal Cross-Linking Expansion

Event summary

  • Glaukos will present multiple scientific abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10-13, 2026.
  • The company is sponsoring a symposium focused on Epioxa™, its FDA-approved epithelium-on corneal cross-linking treatment.
  • Presentations will cover outcomes for glaucoma stents, a keratoconus screening device, and intracameral travoprost implants.
  • Glaukos will exhibit at booth #407 during the ASCRS meeting.

The big picture

Glaukos's presence at ASCRS underscores its commitment to data-driven validation of its technologies, particularly in the competitive glaucoma and corneal health markets. The focus on Epioxa signals a strategic push beyond traditional MIGS, targeting a broader range of corneal disorders. The company’s expanding product portfolio, including iDose TR, positions it to capture a larger share of the $20 billion+ global ophthalmology market, but faces challenges in demonstrating long-term efficacy and securing reimbursement.

What we're watching

Clinical Adoption
The reception of the Epioxa symposium and the presented data will indicate the speed of adoption for this novel corneal cross-linking treatment among ophthalmologists.
Pipeline Progress
Continued data releases regarding the Trabecular Micro-Bypass Stents and intracameral implants will reveal the trajectory of Glaukos’ broader pipeline and its potential to disrupt glaucoma treatment paradigms.
Reimbursement
The long-term success of Epioxa and iDose TR will depend on securing favorable reimbursement rates from payers, which remains a key hurdle for innovative ophthalmic therapies.

Glaukos Launches Novel Keratoconus Treatment, Expanding Ophthalmology Portfolio

Event summary

  • Glaukos launched Epioxa™ HD / Epioxa™, a topical corneal cross-linking therapy for keratoconus, on March 19, 2026.
  • Epioxa represents an incision-free alternative to traditional corneal cross-linking, eliminating the need for corneal epithelium removal.
  • The therapy is FDA-approved for use in adults and pediatric patients aged 13 and older, utilizing enriched oxygen and light.
  • Glaukos plans to increase investments in patient awareness, education, and access programs to address underdiagnosis and undertreatment of keratoconus.

The big picture

Glaukos's entry into this niche market with a differentiated product positions the company to capture a significant share of the keratoconus treatment landscape, which has historically been underserved. The company's focus on patient access programs signals a broader shift towards value-based care and addressing unmet needs within rare disease communities. This launch also reinforces Glaukos's strategy of expanding its portfolio beyond glaucoma treatments into related ophthalmic disorders.

What we're watching

Market Adoption
The success of Epioxa will hinge on physician adoption and patient acceptance of the epithelium-on approach, which could be slower if concerns about efficacy or safety arise.
Reimbursement
How insurance providers reimburse for Epioxa, given its novel approach and potential cost savings compared to traditional methods, will significantly impact its market penetration.
Competitive Response
Existing players in the corneal cross-linking space may accelerate development of competing therapies or strategies to counter Epioxa's advantages, potentially eroding Glaukos's market share.

Glaukos Sales Surge, Profitability Sinks Amidst Transition Costs

Event summary

  • Glaukos reported Q4 2025 net sales of $143.1 million, a 36% year-over-year increase.
  • Full-year 2025 net sales reached $507.4 million, up 32% year-over-year.
  • The company reaffirmed its 2026 net sales guidance of $600 million to $620 million.
  • GAAP net loss for Q4 2025 was $133.7 million, or ($2.32) per diluted share, significantly impacted by a $112.9 million impairment charge.

The big picture

Glaukos' strong revenue growth reflects the increasing demand for its innovative ophthalmic therapies, particularly in the MIGS and dropless drug delivery segments. However, the substantial impairment charge and declining profitability highlight the challenges of integrating acquired assets and managing operating expenses during a period of rapid expansion. The company's future success will depend on its ability to translate revenue growth into sustainable profitability and effectively manage the complexities of its expanding product portfolio.

What we're watching

Margin Pressure
The significant drop in GAAP gross margin, coupled with substantial operating losses, warrants close scrutiny of Glaukos' cost management strategies and ability to maintain profitability as it scales.
Epioxa Adoption
The success of Glaukos' 2026 guidance hinges on the rapid and widespread adoption of Epioxa, and whether it can offset the costs associated with its transition and integration.
Growth Sustainability
While Glaukos has demonstrated impressive revenue growth, the pace at which it can sustain this momentum will depend on its ability to navigate competitive pressures and expand into new markets.

Glaukos Gains FDA Nod for iDose TR Re-Administration

Event summary

  • Glaukos received FDA approval for an NDA labeling supplement allowing for re-administration of its iDose TR device.
  • The approval is based on accumulated clinical evidence demonstrating the safety and tolerability of repeat iDose TR use.
  • Physicians can now re-administer iDose TR more than once in patients with healthy corneas, as defined by endothelial cell density parameters.
  • Clinical trials showed no clinically significant corneal endothelial cell loss through three years and a favorable safety profile with a second administration.

The big picture

This FDA approval expands the potential patient pool for iDose TR and provides physicians with greater flexibility in managing glaucoma treatment. The re-administration allowance addresses a key limitation of the initial approval and could significantly boost the device’s lifetime value. Glaukos’ success in demonstrating long-term corneal safety is a testament to its product development capabilities and reinforces its position in the growing market for minimally invasive glaucoma surgery (MIGS).

What we're watching

Adoption Rate
The pace at which physicians incorporate repeat iDose TR administrations into their treatment protocols will determine the full revenue impact of this approval.
Corneal Health
Continued monitoring of patient corneal health following repeat iDose TR administrations will be critical to maintaining the device’s safety profile and avoiding future regulatory scrutiny.
Competitive Response
Competitors in the glaucoma treatment space may accelerate development of alternative long-duration therapies in response to Glaukos’ expanded iDose TR utility.

Glaukos to Detail 2025 Results Amidst Dropless Therapy Rollout

Event summary

  • Glaukos Corporation (NYSE: GKOS) will release its Q4 and full-year 2025 financial results on February 17, 2026, after market close.
  • A conference call and webcast will follow at 1:30 PM PT (4:30 PM ET) on the same day.
  • Glaukos launched iDose® TR, a long-duration intracameral glaucoma drug therapy, in 2024.
  • The company markets the only FDA-approved corneal cross-linking therapy for keratoconus.

The big picture

Glaukos' focus on novel therapies for glaucoma and related eye disorders positions it within a growing market driven by an aging population and increasing awareness of preventative eye care. The launch of iDose TR represents a significant strategic shift towards long-duration therapies, potentially disrupting traditional glaucoma treatment paradigms. The company's success hinges on demonstrating the clinical and economic benefits of these innovative approaches and navigating the complexities of reimbursement and physician adoption.

What we're watching

Commercialization
The success of iDose TR will be a key indicator of Glaukos' ability to scale its novel procedural pharmaceutical platform and will heavily influence investor sentiment.
Pipeline Progress
The company's continued development and advancement of its dropless platform technologies will be crucial for maintaining a competitive edge in the ophthalmic market.
Market Dynamics
The adoption rate of MIGS and dropless therapies will be influenced by physician comfort levels and reimbursement policies, potentially impacting Glaukos' long-term growth trajectory.

Glaukos Sales Surge 36% in Q4, Reaffirms 2026 Guidance

Event summary

  • Glaukos anticipates preliminary Q4 2025 net sales of $143 million, a 36% increase year-over-year.
  • Full-year 2025 net sales are projected at $507 million, up 32% compared to 2024.
  • iDose TR net sales are expected to contribute approximately $45 million in Q4 and $136 million for the full year.
  • The company holds $283 million in cash and cash equivalents as of the end of Q4 2025.
  • Glaukos reaffirmed its 2026 revenue guidance range of $600 million to $620 million.

The big picture

Glaukos' strong performance underscores the growing demand for minimally invasive glaucoma surgery (MIGS) and dropless therapies, a trend driven by an aging population and a desire for less invasive treatment options. The reaffirmed 2026 guidance suggests confidence in continued market adoption of iDose TR, but the company's valuation will be sensitive to any signs of slowing growth or increased competition in the rapidly evolving ophthalmic space. The company's substantial cash reserves provide flexibility for future acquisitions or pipeline expansion.

What we're watching

Product Adoption
The continued success of iDose TR will be critical for sustaining Glaukos’ growth trajectory, and the Q4 and full-year numbers provide an early indication of its market penetration.
Competitive Landscape
How Glaukos navigates the evolving ophthalmic pharmaceutical and medical technology landscape, particularly with potential competitors entering the dropless therapy space, will determine its long-term market share.
Pipeline Progression
The pace at which Glaukos advances its broader pipeline of novel therapies, beyond iDose TR and Epioxa, will be a key indicator of its future growth potential and ability to maintain a competitive edge.
CID: 647